These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 20682366)

  • 1. Bone loss prevention in cancer: new developments and perspectives.
    Lipton A
    Semin Oncol; 2010 Jun; 37 Suppl 1():S1-2. PubMed ID: 20682366
    [No Abstract]   [Full Text] [Related]  

  • 2. Microgravity and drug effects on bone.
    Shapiro JR
    J Musculoskelet Neuronal Interact; 2006; 6(4):322-3. PubMed ID: 17185807
    [No Abstract]   [Full Text] [Related]  

  • 3. Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
    Brufsky AM
    Oncologist; 2008 Feb; 13(2):187-95. PubMed ID: 18305064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current controversies in bisphosphonate therapy.
    Paul GR
    Orthopedics; 2010 Jul; 33(7):468. PubMed ID: 20608598
    [No Abstract]   [Full Text] [Related]  

  • 5. Bisphosphonates and osteonecrosis: potential treatment or serious complication?
    Goytia RN; Salama A; Khanuja HS
    Orthop Clin North Am; 2009 Apr; 40(2):223-34. PubMed ID: 19358907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of action of bisphosphonates.
    Breuil V
    Rev Rhum Engl Ed; 1999 Jun; 66(6):339-43. PubMed ID: 10418063
    [No Abstract]   [Full Text] [Related]  

  • 7. Maintaining bone health in prostate cancer throughout the disease continuum.
    Saad F; Eastham J
    Semin Oncol; 2010 Jun; 37 Suppl 1():S30-7. PubMed ID: 20682370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of bone loss induced by aromatase inhibitors.
    Gnant M
    Cancer Invest; 2006; 24(3):328-30. PubMed ID: 16809162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: a Z-FAST update.
    Brufsky A
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S13-7. PubMed ID: 16730272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence.
    Smith MR
    Cancer Treat Rev; 2005; 31 Suppl 3():19-25. PubMed ID: 16229955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Open-label trial evaluating the safety and efficacy of zoledronic acid in preventing bone loss in patients with hormone-sensitive prostate cancer and bone metastases.
    Polascik TJ; Given RW; Metzger C; Julian SR; Vestal JC; Karlin GS; Barkley CS; Bilhartz DL; McWhorter LT; Lacerna LV
    Urology; 2005 Nov; 66(5):1054-9. PubMed ID: 16286123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The successful development of bisphosphonates in the therapy of osteoporosis].
    Fassbender WJ; Stumpf UC; Kurth A
    Med Klin (Munich); 2006 Jun; 101 Suppl 1():6-14. PubMed ID: 16826363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Secondary osteoporosis UPDATE. Pathophysiology and management of cancer treatment-induced bone loss/fractures].
    Yoneda T
    Clin Calcium; 2010 May; 20(5):690-9. PubMed ID: 20445280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reducing the risk of cancer treatment-associated bone loss in patients with breast cancer.
    Hadji P; Bundred N
    Semin Oncol; 2007 Dec; 34(6 Suppl 4):S4-10. PubMed ID: 18068489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metastatic bone disease: role of bisphosphonates.
    McKenna MJ; Freaney R; Crown J
    Ir Med J; 1995; 88(6):189. PubMed ID: 8575911
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting bone microenvironment: Clinical implications.
    Gnant M
    Breast; 2015 Nov; 24 Suppl 2():S49-50. PubMed ID: 26238438
    [No Abstract]   [Full Text] [Related]  

  • 18. [Bisphosphonates-associated osteonecrosis of the jaw: review on reported cases].
    Gering A; Grange L; Villier C; Woeller A; Mallaret M
    Therapie; 2007; 62(1):49-54. PubMed ID: 17374348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pamidronate in the prevention of bone loss after liver transplantation: a randomized controlled trial.
    Monegal A; Guañabens N; Suárez MJ; Suárez F; Clemente G; García-González M; De la Mata M; Serrano T; Casafont F; Tome S; Barrios C; Navasa M
    Transpl Int; 2009 Feb; 22(2):198-206. PubMed ID: 18796000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
    J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.